Skip to content

Clinical Observation on the Adjuvant Analgesic Effect of Nalbuphine After Laparoscopic Myomectomy: A Prospective Randomized Controlled Trial

Clinical Observation on the Adjuvant Analgesic Effect of Nalbuphine After Laparoscopic Myomectomy: A Prospective Randomized Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127146
Enrollment
Unknown
Registered
2026-06-25
Start date
2025-10-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Leiomyoma

Interventions

Study group:At 4 hours after operation, nalbuphine 2 mg was diluted with normal saline to 100 mL for intravenous infusion at a rate of 40–50 drops per minute, administered twice daily for 3 consecutiv
Control group:Postoperatively, ibuprofen 0.4 g was diluted with normal saline to 100 mL for intravenous infusion at a drip rate of 40–50 drops per minute, administered twice daily (Bid) for consecutiv

Sponsors

Obstetrics & Gynecology Hospital of Fudan University ,Yangtze River Delta Integration Demonstration Zone(QingPu)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled in the study. 1. Patients undergoing laparoscopic myomectomy who require postoperative analgesia; 2. ASA physical status I–II; 3. Aged 18–65 years, regardless of gender; 4. Body mass index (BMI): 18.5 kg/m^2 <=BMI <=29 kg/m^2; 5. Leiomyoma type: FIGO types 2, 3, 4, 5, and 6 uterine fibroids.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: Subjects with any of the following conditions will be excluded from the trial. 1. Poor compliance and inability to cooperate with the operation; 2. Patients with severe organic diseases, including coronary heart disease, bronchial asthma, severe hypertension, severe hematological dysfunction, significantly abnormal liver and renal function, and obvious electrolyte disorders; 3. History of neurological diseases, chronic pain, drug addiction or alcohol abuse, and long-term use of opioid drugs; 4. Allergy to nalbuphine hydrochloride or its ingredients, or a history of opioid drug allergy; 5. Participation in other clinical drug trials within the recent 4 weeks; 6. Patients with any other conditions deemed unsuitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale;

Secondary

MeasureTime frame
Incidence rate of adverse reactions;Postoperative recovery time;rescue analgesic medication and rescue analgesic dosage;Patient satisfaction score;

Countries

China

Contacts

Public ContactJiang Ting

Obstetrics & Gynecology Hospital of Fudan University ,Yangtze River Delta Integration Demonstration Zone(QingPu)

cherry5202@sina.com+86 188 0173 6756

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026